A/Professor Yoland Antill

A/Professor Yoland Antill

Melbourne
Medical Oncology

Adjunct Associate Professor, Monash University, BMed FRACP MD

Dr Yoland Antill is a Fellow of the Royal Australasian College of Physicians. She trained at Royal North Shore Hospital, in Sydney before completing a fellowship and doctoral studies at the Peter MacCallum Cancer Centre and now works full time across both private and public appointments at Cabrini Health, Royal Melbourne Hospital and Frankston Hospitals as a Medical Oncologist and Cancer Genetics specialist. Her working and research interests are in the management of Breast and Gynaecological cancers.

Dr Antill is a member of the Medical Oncology Group of Australia, the Australian Gynaecological Oncology Group, the Australian and New Zealand Breast Cancer Trials Group, the Private Cancer Physicians of Australia and the American Society of Clinical Oncology. She is a current invited member of the ANZBCTG Supportive Care Subcommittee and the ANZGOG’s Endometrial Cancer working party.

Yoland is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical trials. This includes the Study Chair for a first in its kind Phase 2 study in the treatment of advanced endometrial cancer, the site PI for a number of clinical trials in the management of breast cancer, site PI for several research projects investigating the genetic cause of cancer together with supportive care studies, two based here at Cabrini- one in the management of eyebrow and eyelash loss associated with chemotherapy, the other in the management of vaginal symptoms associated with hormonal therapy for breast cancer.

She has more than 15 years’ experience in both medical oncology and in the diagnosis and management of hereditary cancer syndromes.

Craig Meade

Craig Meade

Sydney, New South Wales
Combined Session
B. Bus, CPA, Dip FP, FPS
Executive Director, DPM Financial Services

Craig joined DPM in 1987, after previous experience with the Australian Taxation Office. Craig holds a Bachelor of Business, Diploma of Financial Planning, he is a Certified Practising Accountant and holds the designation of Specialist in Financial Planning with the Australian Society of CPAs. He is also a Fellow of the Taxation Institute of Australia and an accredited Mortgage Consultant with the MFAA.

Craig is a Director of DPM, a Tax Partner and the Director responsible for the finance advice area of the business.

He is responsible for servicing a client base of high net
worth professionals and advising on taxation, structuring, investments, retirement planning, asset protection and finance.

Dr Benjamin Brady

Dr Benjamin Brady

Melbourne
Medical Oncology

BSc (Hons), BMBS, FRACP

Dr Benjamin Brady is a Medical Oncologist in the Skin and Melanoma Service at Peter Mac and also at Cabrini Health. He completed his Medical Oncology training at the Alfred, Royal Melbourne and Box Hill hospitals. Dr Brady spent many years in laboratory molecular biology at the Ludwig Institute for Cancer Research at the University of Melbourne and subsequently at the University of Colorado Health and Science Centre in Denver, CO, USA. Upon his return to Melbourne in 2002, he has been principal investigator and sub-investigator in many melanoma trials at Cabrini Health and Peter Mac. He has a large melanoma practice in the southeastern suburbs of Melbourne through to far East Gippsland. He is presently Craft Group Leader in Cancer Services at Cabrini Health.

Dr Cameron McLaren

Dr Cameron McLaren

Melbourne
Medical Oncology

MBBS , BSc (Hons) , FRACP

Dr McLaren is a medical oncologist from south-east Melbourne.

An early-adopter of VAD, he has conducted eligibility assessments in over 150 cases of application for VAD. He is a Clinical Moderator of the state-based VAD Community of Practice, an online forum for VAD-involved doctors to discuss their experiences, and is the founding director of VADANZ – Voluntary Assisted Dying practitioners of Australia and New Zealand; a group focused on the practice of, rather than the advocacy for, assisted dying and euthanasia services. He is also conducting a PhD through Monash University on the effect of VAD involvement on grief and bereavement.

Dr Christopher Steer

Dr Christopher Steer

Albury Wodonga
Medical Oncology

MBBS, FRACP

Christopher is a medical oncologist at Border Medical Oncology at the Albury Wodonga Regional Cancer Centre in regional NSW, Australia. He is also a senior lecturer at the UNSW rural clinical school, Albury campus.

After completing training in medical oncology in 2000, Christopher travelled to London to work as a clinical research fellow at Kings College London, Guy’s and St Thomas’ hospital.

Whilst at Guy’s he developed an interest in gynaecological oncology and cancer in the older adult. Christopher was appointed to the MRC as the trial physician for the ICON5 study of combination chemotherapy in women with ovarian cancer.

Christopher has served on the board of the International Society of Geriatric Oncology (SIOG) and was the chair of the national representative committee. He serves on the editorial board of the Journal of Geriatric Oncology. Christopher was chair of the scientific committee of the SIOG annual scientific meeting in Prague in 2016. He was the inaugural chair of the Clinical Oncological Society of Australia (COSA) geriatric interest group. Christopher is the chair of the geriatric study group of the Multinational Association for Supportive Care in Cancer (MASCC).

Christopher was a board member of the Medical Oncology Group of Australia (MOGA) and is the current president of the Private Cancer Physicians of Australia (PCPA). He is a member of ASCO, ESMO, IGCS, MOGA, COSA and MASCC.

Christopher is an investigator at the Border Medical Oncology Research Unit and strives to bring clinical trials to patients in regional Australia. As the coordinator of Independent Learning Projects (ILPs) for the UNSW rural clinical school, Christopher works to foster research skills in local medical students and acts as a mentor for clinician investigators.

Dr Elizabeth Ahern

Dr Elizabeth Ahern

Melbourne
Medical Oncology

BE(Chem)(Hons) MB,BS(Hons) FRACP

Dr Elizabeth Ahern is a Medical Oncologist dedicated to improving outcomes for cancer patients through immune-oncology research. She has a strong interest in preclinical and translational relating to the interaction between immune system and cancer, and immunotherapies. Her clinical interests encompass early-phase trials, immunotherapy, brain cancer, head and neck cancer, and skin cancers including melanoma. Dr Ahern is an early career researcher. She submitted her PhD thesis in July 2020, titled “Targeting Receptor Activator of NF-kB pathways in combination immunotherapy” based on work performed at Queensland Institute of Medical Research Berghofer, developing novel immunotherapy approaches for cancer in preclinical models. She is an investigator on four current translational grants to the value of >AUD$3.5M, focusing on immuno-oncology in lung and colorectal cancer.

Together with national/international collaborators she has developed key novel pre-clinical and observational research which formed the basis for an investigator-sponsored study of neoadjuvant immunotherapy in lung cancer (POPCORN, ACTRN12618001121257). This research also yielded an international patent for a novel immunotherapeutic of which Dr Ahern is a co-owner.

Dr Ahern is an investigator on several other translational research projects in head and neck cancer, melanoma, and brain cancer; and qualitative research in geriatric oncology and cancer care services staff wellbeing in relation to the CoVID-19 pandemic. Dr Ahern values collaboration with diverse members of the cancer multidisciplinary team, and to that end works with Nutrition and Dietetics researchers and head and neck cancer clinicians in projects assessing sarcopenia and epidemiological trends in head and neck cancer, and Nuclear Medicine physicians in novel theranostics targets. She is a participant in the Qld Adult Brain Cancer Workshop through which she is developing a novel immune-oncology therapeutic clinical trial.

Dr Kate Webber

Dr Kate Webber

Melbourne
Medical Oncology

B.Sc (Med) MBBS (Hons 1) FRACP PhD

Dr Kate Webber is a medical oncologist with a keen interest in gynaecological oncology, cancer survivorship and clinical trials.  Kate graduated from the University of New South Wales in 2002 with first class honours and completed her specialty training in medical oncology at St George and Prince of Wales Hospitals in Sydney. She was then appointed the inaugural Survivorship Research Fellow at the National Centre for Cancer Survivorship at the University of New South Wales where she completed a PhD examining long term health and psychosocial issues affecting cancer survivors whilst looking at novel models of care for these patients.

Research arising from her PhD has been presented at scientific meetings for the American Society of Clinical Oncology, International Gynaecological Cancer Society and European Society of Gynaecological Oncology, in addition to Australian meetings. Prior to her appointment at Monash Health, Kate held staff specialist appointments in medical oncology at Prince of Wales Hospital and the Royal Hospital for Women in Sydney, as well as an honorary appointment at Sydney Children’s Hospital. At Prince of Wales Hospital she also served as Clinical Superintendent for Medicine and co-Director of Advanced Physician Training, as well as convenor of the UNSW Human Research Ethics Advisory Panel (Biomedical). Kate is a member of the Cancer Institute NSW eviQ Medical Oncology Reference Committees in gynaecological cancer and sarcoma.

Dr Lucy Fox

Dr Lucy Fox

Melbourne
Haematology

CLINICAL HAEMATOLOGIST

MBBS FRACP FRCPA

Dr Lucy Fox graduated from the University of Melbourne with a double degree in Commerce and Science in 2001 and went on to graduate from Medicine in 2006. Her Haematology Specialist training was completed at the Royal Hobart Hospital, St Vincent’s Hospital (Melbourne), Austin Hospital and the Epworth Hospital and she was granted dual Fellowship of the Royal Australasian College of Physicians and the Royal College of Pathologists of Australasia in 2017.

She is currently undertaking a Molecular Haematology Fellowship at the Peter MacCallum Cancer Centre, and is working towards a higher degree focused on genetic testing in Bone Marrow Failure Syndromes.

Dr Ranjana Srivastava

Dr Ranjana Srivastava

Melbourne, Victoria
Medical Oncology

Dr. Ranjana Srivastava is a medical oncologist, Fulbright scholar and award-winning communicator. She has a particular interest in geriatric oncology and writes a fortnightly column on medicine, ethics and humanity for The Guardian. She is the author of 6 books, numerous essays on communication in the New England Journal of Medicine, and the winner of the Human Rights Literature Prize for her book Dying for A Chat: The Communication Breakdown between Doctors and Patients. She is also the recipient of the Medal of the Order of Australia for contribution to the field of doctor-patient communication.

Dr Richard De Boer

Dr Richard De Boer

Melbourne
Medical Oncology

MBBS FRACP

Dr. Richard de Boer completed his general medical training and then medical oncology training at the Royal Melbourne Hospital. In 1997 he undertook a 3-year breast and lung cancer clinical research Fellowship at the Royal Marsden Hospital in London, working with Professor Ian Smith.
He returned to Melbourne in 2000 and since then has been a consultant medical oncologist working in both public and private practice. He is currently a consultant medical oncologist in both the breast and lung cancer units at the Peter MacCallum Cancer Centre.

His primary breast cancer interests focus on endocrine therapy and mechanisms of resistance, and treatment-induced bone loss and bone metastases. His lung cancer interests focus on targeted therapies, predictors of response/survival, and small cell lung cancer. He is actively involved in clinical research, and is the principal investigator in both local and international studies. He is a member of the Australian New Zealand Breast Cancer Trials Group, and until recently was the head of the Breast Trials Group of Cancer Trials Australia. He has authored articles appearing in journals such as the Journal of Clinical Oncology, Annals of Oncology, The Breast and British Journal of Cancer.

Loading...